Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
1. Clear MoA: High selectivity of inhibiting dual c-Met and AXL
2. Significant preclinical efficacy and less toxic & side effects.
1) Low dose efficacy supior to positive control Eli Lilly ‘s LY2801653
2) Tumor shrinkage in a highly selective c-Met-resistant gastric cancer model after treatment
3. Global competitiveness:
BIC Potential.There is no drug targeting high expression of c-Met in gastric cancer yet. It is expected to be the first drug targeting high expression of c-Met in gastric cancer.
4. Good market potential:
It is estimated that there will be 525,000 gastric cancer patients in 2024, and the gastric cancer drug market will reach 43.2 billion yuan.
1. Asset type: c-Met/AXL inhibitor
2. Indication: Gastric cancer, solid tumor
3. Research phase: IND Approval
4. Cooperation demands: License-out or co-development
5. Research progress：
1．Completed preclinical development and obtained IND approval from NMPA.
2．In vitro experiments, the phosphorylation level of target protein c-Met and downstream proteins AKT and ERK was significantly inhibited.
3．The selective inhibitor showed better tumor suppressing effect than the same dose of LY2801 653 in three gastric cancers with high expression of c-Met.
4．Completed safety profile.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
To enable antibody characterization methodsACROBiosystems has developed a series of enzymes.such as ldeS, SpeB, EndoH, and Endo S proteases, toassist with the characterization of antibodies and theirrelated post-translational modifications (PTMs)
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
This web search service is supported by Google Inc.
A-Z
